Direxion Daily S&P Biotech Bull 3X ETF Rating $250.16 -2.95 (-1.16%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Direxion Daily S&P Biotech Bull 3X ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy 2.66Holdings in LABU have an aggregate rating of Moderate Buy based on 265 analyst ratings issued in the past year covering 15 companies (14.9% of the portfolio).LABU Aggregate Price Target$253.11High Prediction$253.11Average Prediction$253.11Low Prediction$253.11Holdings in LABU have an aggregate price target of $253.11 and a range of $253.11 to $253.11 covering 15 companies (14.9% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3X ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 15 LABU Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings1.89%MRNAModerna$184.45+1.3%Hold$76.72 -58.4%241.9884 of 5 starsTrending NewsAnalyst Forecast1.29%TWSTTwist Bioscience$162.28+2.4%Moderate Buy$103.00 -36.5%121.6655 of 5 starsTrending NewsAnalyst ForecastInsider Trade1.01%ORKAOruka Therapeutics$86.29-4.0%Moderate Buy$133.00 54.1%113.5173 of 5 starsTrending NewsAnalyst ForecastHigh Trading Volume0.98%APGEApogee Therapeutics$135.07Hold$126.77 -6.1%190.8686 of 5 starsPositive News0.94%PRAXPraxis Precision Medicines$281.54-0.2%Moderate Buy$612.42 117.5%202.5169 of 5 starsAnalyst Forecast0.92%HALOHalozyme Therapeutics$113.30+0.8%Moderate Buy$91.20 -19.5%133.1015 of 5 stars0.92%KYMRKymera Therapeutics$114.76-0.6%Moderate Buy$133.21 16.1%261.9411 of 5 starsAnalyst Forecast0.92%NTRANatera$396.00+1.3%Moderate Buy$330.83 -16.5%231.6001 of 5 stars0.87%RVMDRevolution Medicines$192.42+0.9%Moderate Buy$230.15 19.6%233.3124 of 5 starsAnalyst Forecast0.87%CGONCG Oncology$73.10-0.4%Moderate Buy$87.78 20.1%113.0275 of 5 stars0.87%DNTHDianthus Therapeutics$93.75+0.3%Moderate Buy$129.83 38.5%152.503 of 5 stars0.87%PTGXProtagonist Therapeutics$138.71+0.0%Moderate Buy$147.13 6.1%182.0794 of 5 starsPositive News0.85%SYRESpyre Therapeutics$86.72-1.6%Moderate Buy$109.69 26.5%152.432 of 5 stars0.84%TVTXTravere Therapeutics$59.47-0.6%Moderate Buy$69.50 16.9%121.9085 of 5 starsAnalyst Forecast0.83%REGNRegeneron Pharmaceuticals$803.11+0.2%Moderate Buy$802.18 -0.1%243.7165 of 5 starsAnalyst Forecast This page (NYSEARCA:LABU) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3X ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3X ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
